Given that PLP-CD8 altered the trajectory of ongoing demyelinating disease progression within just 2 days of treatment (Figure 2A), we hypothesized that PLP-CD8 could rapidly suppress PLP-specific CD4 T cell responses in vivo. Here, CD4 is linked to demyelinating disease.